These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 17473287)
1. FDA sounds alert on anemia drugs. Mitka M JAMA; 2007 May; 297(17):1868-9. PubMed ID: 17473287 [No Abstract] [Full Text] [Related]
2. FDA approves Eprex for anemia related to AIDS. Nurse Pract; 1989 Sep; 14(9):6. PubMed ID: 2779868 [No Abstract] [Full Text] [Related]
3. The new FDA label for erythropoietin treatment: how does it affect hemoglobin target? Fishbane S; Nissenson AR Kidney Int; 2007 Oct; 72(7):806-13. PubMed ID: 17597700 [TBL] [Abstract][Full Text] [Related]
4. Erythropoietin, the FDA, and oncology. Steinbrook R N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025 [No Abstract] [Full Text] [Related]
5. Safety concerns for two big anemia drugs. Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812980 [No Abstract] [Full Text] [Related]
6. FDA notifications. FDA issues public health advisory about ESAs. AIDS Alert; 2007 May; 22(5):57-8. PubMed ID: 17580370 [No Abstract] [Full Text] [Related]
7. Rebates for anti-anemia drugs draw response from FDA, CMS. Sipkoff M Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732 [No Abstract] [Full Text] [Related]
8. New limits advised for anemia drugs. Mitka M JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074 [No Abstract] [Full Text] [Related]
9. New oversight put in place for physicians giving anemia drugs to patients with cancer. Mitka M JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885 [No Abstract] [Full Text] [Related]
10. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? Besarab A; McCrea JB ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674 [No Abstract] [Full Text] [Related]
11. Weighing the hazards of erythropoiesis stimulation in patients with cancer. Khuri FR N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023 [No Abstract] [Full Text] [Related]
12. FDA panel scrutinizes safety of anti-anemia drugs. Randal J J Natl Cancer Inst; 2004 Jul; 96(14):1061. PubMed ID: 15265966 [No Abstract] [Full Text] [Related]
13. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. Winkelmayer WC J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031 [No Abstract] [Full Text] [Related]
14. FDA committee recommends restricting use of anti-anaemia drug in cancer. Tanne JH BMJ; 2008 Mar; 336(7645):632. PubMed ID: 18356217 [No Abstract] [Full Text] [Related]
15. FDA finalizes REMS program for ESAs; Amgen continues to study risks. Brower V J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565 [No Abstract] [Full Text] [Related]
16. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony. Steensma DP J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668 [No Abstract] [Full Text] [Related]
17. FDA calls for warnings on anaemia drugs amid reports of incentives to doctors. Tanne JH BMJ; 2007 May; 334(7602):1022. PubMed ID: 17510121 [No Abstract] [Full Text] [Related]